Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug

Dow Jones

01/14

By Joe Stonor

Shares in Bayer jumped 6% after Finnish pharmaceutical company Orion predicted strong growth for darolutamide, a prescription prostate-cancer medication on which the two companies partner.

Bayer stock gained 5.8%, or 2.26 euros, to 41.2 euros in early afternoon European trading Wednesday. Shares in Orion also leapt on the announcement, gaining 12%. The Helsinki-listed company is the biggest riser in the Europe-wide Stoxx 600 index.

Bayer and Orion partnered in 2014 to develop darolutamide, with Bayer funding development while Orion handled the drug's manufacturing. Bayer is responsible for taking the drug to market globally.

Darolutamide is Orion's biggest drug by far and its main profit-driver, the company said. Sales of the drug could exceed 1 billion euros ($1.16 billion) in the future, it added.

Orion guided for net group sales for this year of between 1.9 billion euros and 2.1 billion euros and for operating profit of 550 million euros to 750 million euros.

The company hasn't released 2025 earnings, which are due on Feb. 12. It previously guided for 2025 net sales of between 1.64 billion euros and 1.72 billion euros and for operating profit of 410 million euros to 490 million euros.

Darolutamide, which is sold under the brand name Nubeqa, is approved for use in the U.S., U.K. and the European Union.

Bayer shares are trading at a two-year high after rising steadily since last fall. The company's stock is up more than 40% in the three months to Tuesday's close.

Write to Joe Stonor at josephmichael.stonor@wsj.com

(END) Dow Jones Newswires

January 14, 2026 09:02 ET (14:02 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2603611422"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603611422\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603611422?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603611422","market":"sg","top_or_hot":-1,"title":"Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Joe Stonor \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares in Bayer jumped 6% after Finnish pharmaceutical company Orion predicted strong growth for darolutamide, a prescription prostate-cancer medication on which the two companies partner. \n</p>\n<p>\n  Bayer stock gained 5.8%, or 2.26 euros, to 41.2 euros in early afternoon European trading Wednesday. Shares in Orion also leapt on the announcement, gaining 12%. The Helsinki-listed company is the biggest riser in the Europe-wide Stoxx 600 index. \n</p>\n<p>\n  Bayer and Orion partnered in 2014 to develop darolutamide, with Bayer funding development while Orion handled the drug's manufacturing. Bayer is responsible for taking the drug to market globally. \n</p>\n<p>\n  Darolutamide is Orion's biggest drug by far and its main profit-driver, the company said. Sales of the drug could exceed 1 billion euros ($1.16 billion) in the future, it added. \n</p>\n<p>\n  Orion guided for net group sales for this year of between 1.9 billion euros and 2.1 billion euros and for operating profit of 550 million euros to 750 million euros. \n</p>\n<p>\n  The company hasn't released 2025 earnings, which are due on Feb. 12. It previously guided for 2025 net sales of between 1.64 billion euros and 1.72 billion euros and for operating profit of 410 million euros to 490 million euros. \n</p>\n<p>\n  Darolutamide, which is sold under the brand name Nubeqa, is approved for use in the U.S., U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. and the European Union. \n</p>\n<p>\n  Bayer shares are trading at a two-year high after rising steadily since last fall. The company's stock is up more than 40% in the three months to Tuesday's close. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Joe Stonor at josephmichael.stonor@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2026 09:02 ET (14:02 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-14 22:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Joe Stonor \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares in Bayer jumped 6% after Finnish pharmaceutical company Orion predicted strong growth for darolutamide, a prescription prostate-cancer medication on which the two companies partner. \n</p>\n<p>\n  Bayer stock gained 5.8%, or 2.26 euros, to 41.2 euros in early afternoon European trading Wednesday. Shares in Orion also leapt on the announcement, gaining 12%. The Helsinki-listed company is the biggest riser in the Europe-wide Stoxx 600 index. \n</p>\n<p>\n  Bayer and Orion partnered in 2014 to develop darolutamide, with Bayer funding development while Orion handled the drug's manufacturing. Bayer is responsible for taking the drug to market globally. \n</p>\n<p>\n  Darolutamide is Orion's biggest drug by far and its main profit-driver, the company said. Sales of the drug could exceed 1 billion euros ($1.16 billion) in the future, it added. \n</p>\n<p>\n  Orion guided for net group sales for this year of between 1.9 billion euros and 2.1 billion euros and for operating profit of 550 million euros to 750 million euros. \n</p>\n<p>\n  The company hasn't released 2025 earnings, which are due on Feb. 12. It previously guided for 2025 net sales of between 1.64 billion euros and 1.72 billion euros and for operating profit of 410 million euros to 490 million euros. \n</p>\n<p>\n  Darolutamide, which is sold under the brand name Nubeqa, is approved for use in the U.S., U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. and the European Union. \n</p>\n<p>\n  Bayer shares are trading at a two-year high after rising steadily since last fall. The company's stock is up more than 40% in the three months to Tuesday's close. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Joe Stonor at josephmichael.stonor@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2026 09:02 ET (14:02 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BAYRY","symbol_name":"Bayer A.G.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603611422","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603611422","pubTimestamp":1768399320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares in Bayer jumped 6% after Finnish pharmaceutical company Orion predicted strong growth for darolutamide, a prescription prostate-cancer medication on which the two companies partner.Bayer stock gained 5.8%, or 2.26 euros, to 41.2 euros in early afternoon European trading Wednesday. Shares in Orion also leapt on the announcement, gaining 12%. The Helsinki-listed company is the biggest riser in the Europe-wide Stoxx 600 index.Bayer and Orion partnered in 2014 to develop darolutamide, with Bayer funding development while Orion handled the drug's manufacturing. Bayer is responsible for taking the drug to market globally.Darolutamide is Orion's biggest drug by far and its main profit-driver, the company said. Sales of the drug could exceed 1 billion euros  in the future, it added.Orion guided for net group sales for this year of between 1.9 billion euros and 2.1 billion euros and for operating profit of 550 million euros to 750 million euros.The company hasn't released 2025 earnings, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BAYRY":"Bayer A.G.","BK4007":"制药"},"translate_title":"合作伙伴预测前列腺癌药物销售增长，拜耳股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":0.9},"content_text":"By Joe Stonor \n\n\n \n\n\n  Shares in Bayer jumped 6% after Finnish pharmaceutical company Orion predicted strong growth for darolutamide, a prescription prostate-cancer medication on which the two companies partner. \n\n\n  Bayer stock gained 5.8%, or 2.26 euros, to 41.2 euros in early afternoon European trading Wednesday. Shares in Orion also leapt on the announcement, gaining 12%. The Helsinki-listed company is the biggest riser in the Europe-wide Stoxx 600 index. \n\n\n  Bayer and Orion partnered in 2014 to develop darolutamide, with Bayer funding development while Orion handled the drug's manufacturing. Bayer is responsible for taking the drug to market globally. \n\n\n  Darolutamide is Orion's biggest drug by far and its main profit-driver, the company said. Sales of the drug could exceed 1 billion euros ($1.16 billion) in the future, it added. \n\n\n  Orion guided for net group sales for this year of between 1.9 billion euros and 2.1 billion euros and for operating profit of 550 million euros to 750 million euros. \n\n\n  The company hasn't released 2025 earnings, which are due on Feb. 12. It previously guided for 2025 net sales of between 1.64 billion euros and 1.72 billion euros and for operating profit of 410 million euros to 490 million euros. \n\n\n  Darolutamide, which is sold under the brand name Nubeqa, is approved for use in the U.S., U.K. and the European Union. \n\n\n  Bayer shares are trading at a two-year high after rising steadily since last fall. The company's stock is up more than 40% in the three months to Tuesday's close. \n\n\n \n\n\n  Write to Joe Stonor at josephmichael.stonor@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 14, 2026 09:02 ET (14:02 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}